A Phase 1/2 first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of UX053 in patients with glycogen storage disease type IIIDavid Rodriguez‐Buritica, Andrew Grimm, Giacomo P. Comi et al.|Molecular Genetics and Metabolism|2024Cited by 0